[Efficacy of implantable injection port for advanced breast cancer patients]

After breast cancer surgery, it is important to avoid drawing blood sample or injecting chemotherapeutic agents from the involved arm, because severe lymphedema and infection sometimes occurs. Adriamycin, one of the most effective drugs for breast cancer, frequently causes peripheral thrombophlebitis. Therefore, it is often difficult for advanced breast cancer patients to secure IV line and to finish the entire course of chemotherapy. For these reasons, an implantable injection port was applied in 26 breast cancer patients. The status of these patients was metastatic (9 patients), locally advanced (7 patients) and bilateral (10 patients). The average dwell time was 535.8 days with a range of 35 to 1,524 days. The complication events occurred at 0.047/100 catheter days. The results of this study indicate that the implantable injection port provides safe and reliable central venous access and improves the QOL of advanced breast cancer patients.